Human Molecular Genetics Advance Access originally published online on April 7, 2008
Human Molecular Genetics 2008 17(13):2006-2017; doi:10.1093/hmg/ddn098
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms
Cancer Research UK Clinical Centre in Leeds, Leeds Institute for Molecular Medicine, St James’s University Hospital, Beckett Street, Leeds LS9 7TF, UK
* To whom correspondence should be addressed. Tel: +44 1132064913; Fax: +44 1132429886; Email: m.a.knowles{at}leeds.ac.uk
Received February 4, 2008; Accepted March 25, 2008
More than 50% of transitional cell carcinomas of the bladder show loss of heterozygosity of a region spanning the TSC1 locus at 9q34 and mutations of TSC1 have been identified in 14.5% of tumours. These comprise nonsense mutations, splicing mutations, small deletions and missense mutations. Missense mutations are only rarely found in the germline in TSC disease. Therefore, we have examined six somatic missense mutations found in bladder cancer to determine whether these result in loss of function. We describe loss of function via distinct mechanisms. Five mutations caused mutually exclusive defects at mRNA and protein levels. Of these, two mutations caused pre-mRNA splicing errors that were predicted to result in premature protein truncation and three resulted in markedly reduced stability of exogenous TSC1 protein. Primary tumours with aberrant TSC1 pre-mRNA splicing were confirmed as negative for TSC1 expression by immunohistochemistry. Expression was also significantly reduced in a tumour with a TSC1 missense mutation resulting in diminished protein half-life. A single TSC1 missense mutation identified in a tumour with retained heterozygosity of the TSC1 region on chromosome 9 caused an apparently TSC2- and mTOR-independent localization defect of the mutant protein. We conclude that although TSC1 missense mutations do not play a major role in causation of TSC disease, they represent a significant proportion of somatic loss of function mutations in bladder cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. J. McConkey and C. P. Dinney The Molecular, the Bad, and the Ugly: Preventing Bladder Cancer via mTOR Inhibition Cancer Prevention Research, December 1, 2009; 2(12): 1001 - 1002. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M. Platt, C. D. Hurst, C. F. Taylor, W. M. Gregory, P. Harnden, and M. A. Knowles Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer Clin. Cancer Res., October 1, 2009; 15(19): 6008 - 6017. [Abstract] [Full Text] [PDF]
|
|